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Abstract  
Many people who are HIV positive are unaware of their infection status. Estimation of 
the number of people with undiagnosed HIV within a country or region is vital for 
understanding future need for treatment and for motivating testing programs. We 
review the available estimation approaches which are in current use. They can be 
broadly classified into those based on prevalence surveys and those based on 
reported HIV and AIDS cases. Estimation based on prevalence data requires data 
from regular prevalence surveys in different population groups together with 
estimates of the size of these groups. The recommended minimal case reporting 
data needed to estimate the number of patients with undiagnosed HIV are HIV 
diagnoses, including CD4 count at diagnosis and whether there has been an AIDS 
diagnosis in the three months before or after HIV diagnosis, and data on deaths in 
people with HIV. We would encourage all countries to implement several methods 
which will help develop our understanding of strengths and weaknesses of the 
various methods.   
 
 
 
  
Introduction 
 
HIV remains a major public health problem for Europe.  It has been estimated that 
there are approximately 2.2 million people living with the virus in the WHO European 
Region, and approaching 1 million in the European Union and 1.4 million in eastern 
Europe and central Asia1;2.  As HIV does not generally produce symptoms which lead 
to diagnosis around the time of infection, there are many people infected with HIV 
who are not diagnosed.  Consequently, estimates of the total number of people with 
HIV, both undiagnosed and diagnosed, are imprecise.  It is reported that as many as 
one-third of those infected in the European Union countries are unaware of their HIV 
status3 and in some eastern European countries up to 60% of persons living with 
HIV/AIDS are undiagnosed2. One key step towards Europe fully responding to the 
threat of HIV is for all countries within the Region to produce updated estimates of 
the number of people living with HIV.  This is important for understanding the true 
burden of HIV infection, the corresponding need for treatment and for intensifying 
HIV testing; i.e. increasing both the number of people who are tested and the 
frequency with which individuals get tested.  It is important that testing is sufficiently 
frequent and widespread to ensure that people with HIV are diagnosed as rapidly as 
possible to reduce the risk of transmission4 through unprotected sex or sharing of 
injecting equipment and to ensure that individuals receive appropriate and timely 
treatment and care5-10. Estimates of the number of people with HIV are also important 
for countries to use as a basis for projecting healthcare and drug treatment needs. 
 
Currently, there is no consensus approach in European countries to estimating 
numbers of people with HIV.  Different estimation approaches exist, using different 
sources of data, and many countries do not appear to produce any estimates. The 
Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health 
  
Organization (WHO), as part of their global approach to tracking and predicting HIV 
trends in all countries of the world, have produced estimates of numbers of people 
living with HIV, annual numbers of new infections, and of AIDS mortality for every 
country for many years (using an approach based on prevalence surveys described 
below). In spite of methodological improvements and greater within-country 
involvement in use of surveillance data-based approaches, better estimation 
techniques and even greater country involvement would be of benefit. Since many 
methods using different data sources have been proposed, there is a widespread 
perceived need for some guidance on the various methods to set out in relatively 
simple terms the methods that have been developed, the data required to be 
collected, and how to go about the practical steps of actually implementing the 
methods.     
 
Here we review the available approaches in the hope that this will further stimulate 
countries to produce estimates as a step towards a more integrated and 
comprehensive approach across Europe.  It is recognised that the scope of this 
review is limited, and does not encompass methods for assessing trends in HIV 
incidence or modelling HIV transmission, but we believe it will help all European 
countries with obtaining the initial most basic piece of information about their HIV 
epidemic.  
 
 
 
  
Description of data sources and data collection methods 
 
Various sources of data may be used as a basis for estimating the number of people 
living with HIV.  These can be broadly divided into: cross-sectional studies which 
provide estimates of HIV prevalence in specific risk categories such as men who 
have sex with men (MSM) or people who inject drugs (PWID); studies to estimate the 
sizes of these population groups; case reporting of HIV diagnoses, AIDS, and HIV-
related deaths; and cross-sectional studies of patients in care.  
 
Prevalence surveys 
 
Prevalence surveys are performed on a sample of people from a specific risk 
category to obtain an estimate of the proportion of people with HIV infection. 
Estimates are subject to sampling error, which is dependent on the number of people 
in the sample and is quantifiable.  The sample may not be fully representative of the 
risk category, so estimates are subject to bias which cannot always be accounted for, 
although some methods which use multiple prevalence surveys do account for 
possible bias11.    
 
Case reporting 
 
HIV diagnoses 
 
Many countries have surveillance systems so that information on people that have 
been diagnosed with HIV is reported.  Besides basic demographic data, the 
information reported can include: date of diagnosis; the mode of HIV transmission; 
the first CD4 count after diagnosis; whether an AIDS condition or other symptoms 
  
were present at the time of HIV diagnosis; or whether the person was recently 
infected, on the basis of data from antibody assays or a recent negative test. 
 
Reports of HIV diagnoses originate from laboratories or clinicians.  Often, people are 
tested in more than one laboratory and seen in more than one clinic during the 
course of their infection. As cross-linking can be problematic unless patient identifiers 
are accurately recorded, there is a risk of double counting, and in some countries 
privacy laws may prohibit such linkage. Reporting delays are another well-known 
problem. European comparisons are further complicated by the variable quality and 
coverage of national surveillance systems and because national HIV data are not 
reported by all countries in the WHO European Region12.  
 
AIDS cases   
 
Reporting of AIDS cases has traditionally provided the basis for much of the 
surveillance of the epidemic, but has been perceived as less useful since the advent 
of effective therapy13. However, as cases of AIDS in people who have not previously 
been diagnosed with HIV can provide information on the size of the undiagnosed 
population, this remains an important source of data that should continue to be 
prioritized.  
 
Deaths in people with HIV 
 
Several methods for estimating the number of people with HIV involve estimating the 
number of people who have ever been infected with HIV.  As calculation of the 
number of people living with HIV requires subtraction of the number who have died, 
reporting of deaths in people with HIV is important for generating estimates. Death is 
reported by clinicians but also, in several countries, linkage is made to national death 
  
registers so that deaths in people with diagnosed HIV can be identified. This relies on 
accurate identifier information for cross-linking data. The number of deaths is subject 
to bias as some people living with HIV may never be diagnosed as HIV-positive, 
even at death. 
 
Cross-sectional assessment of people seen for HIV care 
 
In some European countries, such as the United Kingdom, clinicians are regularly 
asked to report on all people seen for care. The data include information such as the 
latest CD4 count and whether the patient is on therapy. In the ideal situation, such as 
in the Netherlands, all people diagnosed with HIV are followed longitudinally so that 
all information collected as part of routine clinical care is available for public health 
purposes. 
 
 
 
  
Approaches to estimating the number of people with 
undiagnosed HIV 
 
Methods based on prevalence surveys 
 
The estimation of overall HIV prevalence by combining estimates of HIV prevalence 
within risk categories with estimates of the size of each risk category is known as the 
direct method14-16. The population is divided up according to HIV risk category: the 
risk categories used may vary by setting. Within each category, HIV prevalence and 
the number of people are estimated, then multiplied together to produce an estimated 
number with HIV: this is summed across all risk categories to estimate the total 
number with HIV. The total number with undiagnosed HIV can be obtained by 
subtracting the number with diagnosed HIV, if this is available, either overall, or 
within each category prior to summing across categories. In a variation on this 
approach, if the information is available then the prevalence of undiagnosed HIV in 
each risk category may be estimated directly from the prevalence survey.  
 
This approach provides the basis for UNAIDS/WHO estimates via the Workbook and 
Estimation and Projection Package (EPP) approaches17-19, the latter using a 
Bayesian approach to estimate uncertainty. Workbook and EPP are closely linked 
with the Spectrum programme18;20.   
 
Prevalence survey sampling issues 
 
It is unlikely that HIV prevalence will be uniform across a transmission risk category. 
For example, for MSM and PWID there is a range of risk activity, and it is probable 
that HIV prevalence will increase with increasing risk activity. If a prevalence survey 
  
uses a sampling approach targeting those with the highest levels of risk, then 
applying this prevalence to the total estimated population of MSM or PWID will 
overestimate HIV prevalence. A potential solution to this, adopted in some 
applications of this method, is to treat high and low risk MSM as separate risk 
groups. This reduces the possibility of bias, but requires estimation of the respective 
sizes and HIV prevalence of the separate risk groups. 
 
Estimation of the size of population groups with high risk behaviour 
 
A discussion of various methods for estimating the size of risk categories used in 
prevalence surveys is contained in UNAIDS/WHO guidelines11, and some 
developments and applications are discussed in a recent report of the UNAIDS 
Reference Group on Estimates, Modelling and Projections21. The most appropriate 
method varies according to risk category. Capture-recapture, multiplier, census and 
nomination methods have all been used. Other indirect estimation methods - such as 
benchmark calculations which make use of police arrests, drug dependence 
treatment and drug related deaths and other existing data sources - are increasingly 
used to estimate the size of PWID populations. The size of some populations (such 
as MSM and PWID) may also be estimated directly from household surveys, 
however they generally underestimate the prevalence of stigmatized behaviours. The 
network scale-up method has recently been developed and field testing is ongoing: 
this method uses data on a survey respondent’s network of acquaintances rather 
than data on the respondent themselves. All of these methods suffer from potential 
biases.   
 
The Multi-parameter Evidence Synthesis (MPES) method 
 
  
The MPES method22-24 is based on the principles of prevalence surveys and 
estimation of the size of transmission risk populations but, unlike other approaches, 
is designed to include the often multiple sources of data providing information on 
both prevalence and risk size. The MPES method synthesises the multiple diverse 
types of evidence, performing a formal statistical ‘triangulation’ of these data, in a 
framework that also allows the detection of possible conflicts between evidence 
informing the same quantity or parameter. Conflicts may arise due to the bias that 
must exist in some sources of information and the MPES method allows explicit 
modelling of these biases to resolve inconsistency.  Estimation is performed using a 
Bayesian approach, ensuring the correct and coherent propagation of uncertainty in 
the data and estimation process through to final estimates of the numbers with HIV.  
 
 
Methods based on reporting of HIV/AIDS diagnoses involving calculation of 
cumulative incidence of HIV   
 
The methods described in this section are all primarily for estimating the historical 
incidence of HIV infection as well as the current incidence, although the latter is 
estimated with considerable uncertainty. The cumulative number of deaths in people 
with HIV is required to estimate current prevalence: this is subtracted from the 
cumulative HIV incidence during the epidemic. 
 
The back-calculation method was initially described and used early in the HIV 
epidemic25;26. At the time, effective treatment was not available so HIV-positive 
individuals progressed to AIDS according to the natural, variable course of infection. 
Using the number of reported AIDS cases in each year, and the assumed known 
distribution of time from infection to AIDS, it was possible to estimate the number of 
people infected in each previous year. If data on cumulative HIV-related deaths were 
  
available and accurate, it was possible to estimate the number of people living with 
HIV and hence, using the number diagnosed with HIV, the number of people living 
with undiagnosed HIV. 
 
With the use of effective antiretroviral therapy (ART), most people with HIV do not 
progress to AIDS. Therefore back-calculation models based exclusively on incident 
AIDS cases are no longer viable because the distribution of time from infection to 
AIDS is difficult to estimate. Furthermore, even if it were possible to estimate the 
distribution of time from infection to AIDS, this method could not provide reliable 
information on recent trends in HIV incidence because individuals currently 
diagnosed with AIDS are likely to have been infected with HIV for some time. 
Consequently, this method is generally considered to be no longer relevant. The 
back-calculation method has been modified to consider the number of HIV diagnoses 
instead of the number of AIDS cases27;28. Some variants of this method are described 
below29-33. Each of the methods described here makes use of techniques for 
smoothing the incidence curve. They also all make some correction for reporting 
delay of AIDS and HIV cases.  We refer to each of these approaches as a method, 
although they are in some ways variants of the same method. These methods are 
mainly applied to the adult population only. 
  
Cambridge method29  
 
Sweeting et al. (MRC Biostatistics Unit, Cambridge, United Kingdom) describe 
Bayesian back-calculation using a multi-state model, and apply it to United Kingdom 
Health Protection Agency (HPA) data on HIV in MSM29. The method is re-considered 
by Birrell and applied to an updated dataset34. The data required are number of new 
HIV diagnoses per calendar quarter, with data on AIDS diagnosis occurring in the 
same calendar quarter (late diagnosis). CD4 counts around diagnosis for a subset of 
  
the diagnoses are strongly recommended but not essential, and data should be 
stratified by risk group. 
 
Atlanta method30 
 
Hall et al. (Center for Disease Control and Prevention, Atlanta, United States) 
describe their extended back-calculation method and use it to generate estimates of 
HIV incidence in the United States, and compare with estimates obtained using 
assays that differentiate between recent and longstanding infection30. The extended 
back-calculation method was subsequently used to obtain estimates of HIV 
prevalence in the United States, including estimates of undiagnosed HIV 
prevalence35;36. In addition to demographic information, the data required are the 
number of new HIV diagnoses per calendar year with information on whether AIDS 
was diagnosed within the same calendar year as HIV (disease severity).   
 
Ottawa / Sydney method 31 
 
Wand et al. (National Centre in HIV Epidemiology and Clinical Research, Sydney, 
Australia) describe and adopt a methodology developed by colleagues in the Public 
Health Agency of Canada. Their extended back-calculation method is used to 
reconstruct the HIV epidemic in Australia in the MSM, PWID, and heterosexual 
exposure categories31. The same method was also used in different provinces in 
Canada, to determine the national HIV incidence and prevalence37. The data 
required are HIV diagnoses, with additional data on whether the HIV infection is 
recent or not using either enhanced surveillance (evidence of a prior negative test, or 
a diagnosis of seroconversion illness, or an indeterminate western blot within one 
year of HIV diagnosis), or using laboratory techniques. This methodology does not 
  
require a test for a biomarker such as CD4 count. The method also uses data on 
AIDS diagnoses in years before effective treatment was available.   
 
Paris method 32 
 
Ndawinz et al. (INSERM U943, Paris, France) describe an extended back-calculation 
method, which is used to estimate both the incidence of HIV infection in France and 
the time-dependent intervals of time from infection to diagnosis in different 
transmission categories32. If HIV and AIDS case surveillance has been in place for 
some time, the method can also be used to estimate the HIV prevalence and the 
number of undiagnosed people with HIV. The data required are times of HIV 
diagnosis, risk category and clinical status at diagnosis divided into three categories: 
primary infection, AIDS and other clinical statuses.  
 
Bordeaux method 33 
 
The method described by Sommen et. al. (INSERM U897, Bordeaux, France) is 
based on a Markov model which, unlike the other methods in this section, models 
treatment uptake. The method is illustrated using HIV/AIDS surveillance data on 
MSM in France. The data required are HIV and AIDS diagnosis data. The method is 
described in a context where HIV diagnosis data is only available for the most recent 
years, but can be adapted for situations where HIV diagnosis monitoring has been in 
place for longer. 
 
 
Methods based on CD4 count and simultaneous HIV/AIDS 
 
  
Each year, a proportion of the undiagnosed population will present with AIDS and be 
diagnosed with HIV at the same time (referred to as simultaneous HIV/AIDS 
diagnosis). As the incidence of AIDS at a given CD4 count can be estimated from 
cohort studies, we can directly use data on the number of simultaneous HIV/AIDS 
diagnoses during a given year to estimate the size of the undiagnosed population for 
a given risk group38;39. Two variations of this method are described, both of which 
require the number of simultaneous HIV/AIDS diagnoses in a year, and assume that 
the underascertainment rate of simultaneous HIV/AIDS diagnoses can be estimated. 
The uncertainty associated with each estimate is evaluated by assuming the AIDS 
incidence varies according to a Normal distribution, and that the number of 
simultaneous HIV/AIDS diagnoses varies according to a Poisson distribution.  Both 
methods could be refined by assuming that a continuous function describes the 
relationship between CD4 count and AIDS rate. 
 
London method 1 
 
This requires the CD4 count at HIV/AIDS diagnosis. For each CD4 count stratum, the 
number of people with undiagnosed HIV can be estimated by dividing the number of 
simultaneous HIV/AIDS diagnoses in that stratum by the CD4-specific AIDS rate. 
Summing across all strata gives the total number with undiagnosed HIV.  For high 
CD4 count strata in which the AIDS rate is low the estimates will be associated with 
considerable uncertainty. 
 
London method 2 
 
This method assumes that CD4 count in the undiagnosed population can be 
approximated by the CD4 count at diagnosis in patients presenting for care with 
asymptomatic HIV. Consequently data may also be required on whether patients are 
  
asymptomatic at HIV diagnosis, if this information is not available from appropriate 
cohort studies.  
  
Transmission model approach 
 
For some countries, models which reconstruct the processes of transmission of HIV, 
diagnosis, treatment and occurrence of AIDS and death have been developed and 
fitted to multiple data sources40;41.  The purpose of such models is not restricted to 
estimation of the current number with HIV but this nevertheless can be obtained from 
them.  These methods are not suitable for use by countries which are initially 
focussed only on obtaining an estimate of the number of people with HIV.  However, 
their use is possible when there are multiple sources of data and it may be possible 
for countries to set up ad hoc collaborations to implement such models, which are 
useful for analysing trends and the reasons behind them, and for predicting 
incidence.    
 
  
Discussion 
 
We have reviewed the various methods for estimating the number of people with 
undiagnosed HIV.  Each approach has its strengths but also each has limitations.  All 
methods involve significant assumptions which generally cannot be checked.  The 
main limitation of the approach based on prevalence surveys is the need to match up 
risk categories for which prevalence estimates have been obtained with estimates of 
the size of those categories.  If, for example, prevalence surveys tend to be carried 
out in MSM with relatively high numbers of unprotected sex partners it is important 
that this estimate is applied to a population of similar risk activity, and not to the 
entire population of men who have reported a male partner in the past few years.   
 
The methods based on estimation of cumulative incidence of HIV infections aim to 
reconstruct the epidemic and have the key limitation that it is difficult to distinguish 
changes in diagnosis rates from changes in incidence.  This distinction may be 
helped by additional data at diagnosis on whether AIDS is present, the CD4 count, or 
whether infection was recent.  These methods also rely on the assumption that all 
people infected with HIV will be diagnosed as such, either during their life or at death, 
which may be true to a varying extent in different countries depending on the 
countries’ health infrastructure and HIV testing practices. They also require data on 
the cumulative total number of deaths in people with HIV, which may be 
underestimated by the registered number of deaths. 
 
The methods based on data on surveillance of simultaneous HIV/AIDS cases are 
limited by the assumption that the CD4 count at diagnosis in asymptomatic people 
reflects the distribution in the undiagnosed population. The estimates of numbers of 
undiagnosed people with high CD4 count may be unstable due to a very large 
  
multiplication factor being applied to those presenting with simultaneous HIV/AIDS at 
higher CD4 counts.  The methods also rely heavily on high levels of ascertainment of 
simultaneous HIV/AIDS cases.   
 
It is desirable that as many of the approaches as possible be implemented to build up 
the most reliable overall picture of the number of people living with HIV and the 
bounds of uncertainty around this.  In the short-term, the methods that a country can 
apply will be dictated by the data sources available, but this review is intended to also 
provide guidance to countries on which data they wish to start to collect. The data 
required to apply the available methods are summarised in Figure 1. 
 
While methods involving prevalence surveys have the potential to provide a 
comprehensive assessment of the state of the epidemic, the collection of case 
reporting data also has an important role in allowing the estimation of the number of 
people with undiagnosed HIV. We recommend that in order to produce estimates of 
the number of patients with undiagnosed HIV, the minimal case reporting data that a 
country should collect are HIV diagnoses, including CD4 count at diagnosis and 
whether there has been an AIDS diagnoses in the three months before or after HIV 
diagnosis, and data on deaths in people with HIV. However, to allow a greater range 
of methods to be used, we suggest that more extensive surveillance data be 
collected, including data on whether infection is recent. 
 
As more European countries employ multiple methods42, it may become clear 
whether there are systematic differences in results from the various estimation 
approaches, with perhaps one method producing higher or lower estimates than 
others.  Efforts to try to understand the reasons behind such discrepancies will help 
to move us forward with improving data collection methods. 
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Figure 1. Summary of available methods and the data required  
Data sources Methods
Prevalence surveys
Direct method / workbook / EPP / Spectrum
MPES
Cumulative incidence of HIV
Cambridge
Atlanta
Ottawa / Sydney
Paris
Bordeaux
CD4 count and simultaneous HIV/AIDS
London 1
London 2
Prevalence surveys
Estimation of size of risk categories
Deaths in people with HIV
HIV diagnoses
AIDS cases
Additional data at HIV diagnosis
CD4 count
Whether infection is recent
Presence of HIV-related symptoms
Simultaneous AIDS diagnosis
Cambridge
Atlanta
Ottawa / Sydney
Paris
London 1
London 2
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